Gemina Laboratories Ltd. Stock

Gemina Laboratories Ltd. is a Canada-based biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers testing platforms for a range of pathogens that affect human health and wellness. The Company operates in the in vitro diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. Its development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. It operates within a single segment, being the research, development and commercialization of in-vitro diagnostics. Its technologies include dual affinity binding mechanism, gold binding protein, cellulose binding protein and more surface binding proteins. Its products include LEGIO X, which is a COVID-19 rapid antigen test, and LEGIO XI, which is a multiplex device that can detect and distinguish between influenza types A and B with no cross reactivity. LEGIO products in development include respiratory syncytial virus and tuberculosis.